MDM2 for the practicing pathologist: A primer
Journal of Clinical Pathology, ISSN: 1472-4146, Vol: 76, Issue: 5, Page: 285-290
2023
- 2Citations
- 16Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- Captures16
- Readers16
- 16
- Mentions1
- News Mentions1
- News1
Most Recent News
Studies from Rutgers University - The State University of New Jersey Have Provided New Information about Genomics and Genetics (Mdm2 for the Practicing Pathologist: a Primer)
2023 APR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Researchers detail new data in Genomics and Genetics. According
Article Description
The mouse double minute 2 (MDM2) gene is located on the long arm of chromosome 12 and is the primary negative regulator of p53. The MDM2 gene encodes an E3 ubiquitin-protein ligase that mediates the ubiquitination of p53, leading to its degradation. MDM2 enhances tumour formation by inactivating the p53 tumour suppressor protein. The MDM2 gene also has many p53-independent functions. Alterations of MDM2 may occur through various mechanisms and contribute to the pathogenesis of many human tumours and some non-neoplastic diseases. Detection of MDM2 amplification is used in the clinical practice setting to help diagnose multiple tumour types, including lipomatous neoplasms, low-grade osteosarcomas and intimal sarcoma, among others. It is generally a marker of adverse prognosis, and MDM2-targeted therapies are currently in clinical trials. This article provides a concise overview of the MDM2 gene and discusses practical diagnostic applications pertaining to human tumour biology.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85152695617&origin=inward; http://dx.doi.org/10.1136/jcp-2022-208687; http://www.ncbi.nlm.nih.gov/pubmed/36898827; https://jcp.bmj.com/lookup/doi/10.1136/jcp-2022-208687; https://dx.doi.org/10.1136/jcp-2022-208687; https://jcp.bmj.com/content/76/5/285
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know